Introduction
Skeletal muscle atrophy is common to several conditions and disease states including fasting, cancer, systemic inflammation and metabolic derangements (uremia, diabetes) as well as after denervation and in motor neuron degeneration. More chronic conditions associated with sarcopenia include disuse, aging, drugs (steroids), spaceflight and hypoxia. In the early stages of experimental muscle atrophy, the ubiquitin ligase Atrogin-1 (MAFbx) is strongly induced (Lecker et al., 2004) . Atrogin-1 (MAFbx) is a skeletal and a cardiac muscle-specific F-box containing protein that binds to the other components of the SCF (Skp1-Cullin1-F-box protein) complex family of E3 ubiquitin ligases (Gomes et al., 2001; Li et al., 2004) . The F-box proteins generally function as adaptors targeting specific substrates for ubiquitin-dependent degradation through protein-protein interaction domains (Li et al., 2004) . Upon fasting for instance, the rise in Atrogin-1 expression precedes muscle loss (Gomes et al., 2001) . Animals, deficient in Atrogin-1 or the related MuRF1 ligase are resistant to muscle atrophy following denervation (Sacheck et al., 2004; Sandri et al., 2004; Stitt et al., 2004) . On the other hand, Atrogin-1 expression inhibits calcineurin-dependent cardiac hypertrophy (Li et al., 2004) . In many of these instances, suppression of the IGF-1/ PI3-K/Akt signaling pathway leads to the activation of Foxo family transcription factors and enhancement of Atrogin-1/MAFbx expression (Bodine et al., 2001; Sandri et al., 2004; Skurk et al., 2005) . Conversely, IGF-1 stimulation reduces Atrogin expression and rescues dexamethasone provoked myofibrillar protein degradation (Sacheck et al., 2004; Stitt et al., 2004) . The only degenerative human muscle wasting disorder studied extensively for Atrogin-1 upregulation is amyotrophic lateral sclerosis (ALS), which arises from chronic denervation and sprouting (Leger et al., 2006) . Dystrophic and myositic processes confined to skeletal muscle also activate a muscle wasting program (Lecker et al., 1999) , but Atrogin-1 induction has not been investigated. Inclusion body myositis (IBM) is a progressive inflammatory myopathy for which there is no effective treatment. Often sporadic and affecting men, it is the most common acquired muscle disease after age 50. Typical features are asymmetric, slowly progressive muscle weakness and atrophy with predilection for quadriceps and forearm flexors and frequent dysphagia (Griggs et al., 1995; Tawil and Griggs, 2002) . Microscopically, skeletal muscle displays focal endomysial infiltrations of inflammatory mononuclear cells, CD8-T cell invasion of non-necrotic myofibers, modest numbers Neurobiology of Disease 46 (2012) [463] [464] [465] [466] [467] [468] [469] [470] [471] [472] [473] [474] [475] 
